Future directions with taxane therapy

F. Cabral; E. Trimble; E. Reed; G. Sarosy

doi:10.1016/S0889-8588(05)70152-0

Future directions with taxane therapy

F. Cabral, E. Trimble, E. Reed, G. Sarosy

Research output: Contribution to journal › Article › peer-review

8 Scopus citations

Abstract

The potential biochemical and genetic mechanisms by which a cell might experience a decreased sensitivity to taxanes and other drugs of this class are discussed in the first part of this article. The use of taxanes in the current gynecologic-oncologic clinical setting is reviewed with special consideration given to the pharmacokinetics of taxane in relation to dose intensity and length of administration.

Original language	English (US)
Pages (from-to)	21-41
Number of pages	21
Journal	Hematology/Oncology Clinics of North America
Volume	13
Issue number	1
DOIs	https://doi.org/10.1016/S0889-8588(05)70152-0
State	Published - 1999
Externally published	Yes

ASJC Scopus subject areas

Hematology
Oncology

Access to Document

10.1016/S0889-8588(05)70152-0

Cite this

@article{b6c735b59c994f0db81c482752359a05,

title = "Future directions with taxane therapy",

abstract = "The potential biochemical and genetic mechanisms by which a cell might experience a decreased sensitivity to taxanes and other drugs of this class are discussed in the first part of this article. The use of taxanes in the current gynecologic-oncologic clinical setting is reviewed with special consideration given to the pharmacokinetics of taxane in relation to dose intensity and length of administration.",

author = "F. Cabral and E. Trimble and E. Reed and G. Sarosy",

year = "1999",

doi = "10.1016/S0889-8588(05)70152-0",

language = "English (US)",

volume = "13",

pages = "21--41",

journal = "Hematology/Oncology Clinics of North America",

issn = "0889-8588",

publisher = "W.B. Saunders Ltd",

number = "1",

}

TY - JOUR

T1 - Future directions with taxane therapy

AU - Cabral, F.

AU - Trimble, E.

AU - Reed, E.

AU - Sarosy, G.

PY - 1999

Y1 - 1999

N2 - The potential biochemical and genetic mechanisms by which a cell might experience a decreased sensitivity to taxanes and other drugs of this class are discussed in the first part of this article. The use of taxanes in the current gynecologic-oncologic clinical setting is reviewed with special consideration given to the pharmacokinetics of taxane in relation to dose intensity and length of administration.

AB - The potential biochemical and genetic mechanisms by which a cell might experience a decreased sensitivity to taxanes and other drugs of this class are discussed in the first part of this article. The use of taxanes in the current gynecologic-oncologic clinical setting is reviewed with special consideration given to the pharmacokinetics of taxane in relation to dose intensity and length of administration.

UR - http://www.scopus.com/inward/record.url?scp=0033044492&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033044492&partnerID=8YFLogxK

U2 - 10.1016/S0889-8588(05)70152-0

DO - 10.1016/S0889-8588(05)70152-0

M3 - Article

C2 - 10080068

AN - SCOPUS:0033044492

SN - 0889-8588

VL - 13

SP - 21

EP - 41

JO - Hematology/Oncology Clinics of North America

JF - Hematology/Oncology Clinics of North America

IS - 1

ER -

Future directions with taxane therapy

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this